Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L03 IMMUNOSTIMULANTS
L03A IMMUNOSTIMULANTS
L03AX Other immunostimulants
L03AX21 Elapegademase
D11017 Elapegademase (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
Elapegademase
D11017 Elapegademase (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
395 Enzyme preparations
3959 Others
D11017 Elapegademase (USAN/INN); Elapegademase (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Adenosine deaminase
ADA* [HSA_VAR:100v1]
D11017 Elapegademase (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11017
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11017
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11017
Pharmacogenomic biomarkers [br08341.html]
Germline mutations in genetic disorder treatments
D11017